Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma

Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Zhongchao Li, Lei Zhao, Bo Zhang, Jinbo Yue, Xuetao Shi, Kai Cui, Lei Li, Chengsheng Zhang, Pengfei Sun, Jingtao Zhong, Zhongchao Li, Lei Zhao

Abstract

Introduction: Liver resection is the mainstay of curative-intent treatment for hepatocellular carcinoma (HCC), but the postoperative 5-year recurrence rate reaches 70%, and there are no adjuvant or neoadjuvant therapies recommended by major HCC guidelines that can reduce the risk of recurrence. In the recent decade, significant progress has been achieved in the systemic treatment of HCC, mainly from immune checkpoint inhibitors (ICIs) and targeted therapy. In other malignancies, ICIs in the neoadjuvant setting have shown better outcomes than in the adjuvant setting. On the other hand, the addition of radiation to ICIs incrementally improves the systemic response to ICIs. Neoadjuvant therapy of ICIs plus stereotactic body radiotherapy (SBRT) has shown promising results in several types of solid tumours but not HCC.

Methods and analysis: Here, we describe a phase Ib clinical trial of neoadjuvant SBRT plus PD-1 (tislelizumab) prior to hepatic resection in HCC patients. Prior to resection, eligible HCC patients will receive 8 Gy×3 fractions of SBRT together with two cycles of tislelizumab with an interval of 3 weeks. HCC resection is scheduled 4 weeks after the second dose of tislelizumab, followed by adjuvant tislelizumab for 1 year. We plan to enrol 20 participants in this trial. The primary study endpoints include the delay of surgery, tumour response and safety and tolerability of the sequential SBRT/tislelizumab. Other endpoints are the disease-free survival and overall survival rates every 3 or 6 months after the surgery.

Ethics and dissemination: This trial was approved by the Ethics Committee of Shandong Cancer Hospital and Institute (SDZLEC2022-021-01). The final results of this trial will be published in a peer-reviewed journal after completion.

Trial registration number: NCT05185531.

Keywords: Clinical trials; Hepatobiliary tumours; RADIOTHERAPY.

Conflict of interest statement

Competing interests: LZ is on the speakers’ bureau for BeiGene, Bayer, MSD, Roche, Innovent and Hengrui Medicine. This trial is partly funded by BeiGene.

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

References

    1. Sung H, Ferlay J, Siegel RL, et al. . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209–49. 10.3322/caac.21660
    1. Villanueva A. Hepatocellular carcinoma. N Engl J Med 2019;380:1450–62. 10.1056/NEJMra1713263
    1. Roayaie S, Jibara G, Tabrizian P, et al. . The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology 2015;62:440–51. 10.1002/hep.27745
    1. European Association for the Study of the Liver. Electronic address, e.e.e. and L . European association for the study of the, EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:182–236.
    1. Marrero JA, Kulik LM, Sirlin CB, et al. . Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American association for the study of liver diseases. Hepatology 2018;68:723–50. 10.1002/hep.29913
    1. von Felden J, Karkmann K, Ittrich H, et al. . Sequential systemic treatment in advanced hepatocellular carcinoma is able to prolong median survival to more than 3 years in a selected real-world cohort. Visc Med 2021;37:87–93. 10.1159/000507381
    1. Zhang T, Song X, Xu L, et al. . The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions. Cancer Immunol Immunother 2018;67:1079–90. 10.1007/s00262-018-2160-x
    1. Kudo M. Adjuvant immunotherapy after curative treatment for hepatocellular carcinoma. Liver Cancer 2021;10:399–403. 10.1159/000518584
    1. Su Y-Y, Li C-C, Lin Y-J, et al. . Adjuvant versus neoadjuvant immunotherapy for hepatocellular carcinoma: clinical and immunologic perspectives. Semin Liver Dis 2021;41:263–76. 10.1055/s-0041-1730949
    1. Versluis JM, Long GV, Blank CU. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat Med 2020;26:475–84. 10.1038/s41591-020-0829-0
    1. Blank CU, Rozeman EA, Fanchi LF, et al. . Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat Med 2018;24:1655–61. 10.1038/s41591-018-0198-0
    1. Song Y, Straker RJ, Xu X, et al. . Neoadjuvant versus adjuvant immune checkpoint blockade in the treatment of clinical stage III melanoma. Ann Surg Oncol 2020;27:2915–26. 10.1245/s10434-019-08174-1
    1. Kaseb AO, Hasanov E, Cao HST, et al. . Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022;7:208–18. 10.1016/S2468-1253(21)00427-1
    1. Marron TU, Fiel MI, Hamon P, et al. . Neoadjuvant cemiplimab for resectable hepatocellular carcinoma: a single-arm, open-label, phase 2 trial. Lancet Gastroenterol Hepatol 2022;7:219–29. 10.1016/S2468-1253(21)00385-X
    1. Wei X, Jiang Y, Zhang X, et al. . Neoadjuvant three-dimensional conformal radiotherapy for resectable hepatocellular carcinoma with portal vein tumor thrombus: a randomized, open-label, multicenter controlled study. J Clin Oncol 2019;37:2141–51. 10.1200/JCO.18.02184
    1. Sharabi AB, Lim M, DeWeese TL, et al. . Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 2015;16:e498–509. 10.1016/S1470-2045(15)00007-8
    1. Lee YH, Tai D, Yip C, et al. . Combinational immunotherapy for hepatocellular carcinoma: radiotherapy, immune checkpoint blockade and beyond. Front Immunol 2020;11:568759. 10.3389/fimmu.2020.568759
    1. Deutsch E, Chargari C, Galluzzi L, et al. . Optimising efficacy and reducing toxicity of anticancer radioimmunotherapy. Lancet Oncol 2019;20:e452–63. 10.1016/S1470-2045(19)30171-8
    1. Gill S, Nowak AK, Bowyer S. Clinical evidence for synergy between immunotherapy and radiotherapy (SITAR). J Med Imaging Radiat Oncol 2022. 10.1111/1754-9485.13441
    1. Williamson CW, Sherer MV, Zamarin D, et al. . Immunotherapy and radiation therapy sequencing: state of the data on timing, efficacy, and safety. Cancer 2021;127:1553–67. 10.1002/cncr.33424
    1. Altorki NK, McGraw TE, Borczuk AC, et al. . Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial. Lancet Oncol 2021;22:824–35. 10.1016/S1470-2045(21)00149-2

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅